GTJA Investment is a private equity firm specializing in angel, early, mid venture, mergers and acquisition strategies.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
GTJA Investment is a private equity firm specializing in angel, early, mid venture, mergers and acquisition strategies.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
12/2016 | Danxia | Series A | 1.4M |
4/2021 | VivaVision Biotech | Series D | 46.2M |
8/2017 | Sansure Biotech | Venture Round | - |
9/2017 | Wellem | Series B | 30M |
9/2018 | Jianke | Series B | 130M |
1/2020 | Lachesis | Series B | 0 |
12/2021 | DK MedTech | Series C | - |
12/2019 | Elpiscience Biopharmaceuticals | Series B | 0 |
8/2021 | Boan Biotech | Series B | 13.9M |
12/2017 | Yunshan Medical | Series A | 20M |
1/2020 | CF PharmTech | Series E | 90.5M |
4/2011 | Zhongding Technology | Venture Round | 270.9k |
11/2012 | Ximalaya Xinxi Keji | Angel Round | 481.8k |
8/2018 | Teligene | Series B | - |
12/2016 | ASK E-health | Series A | 14.4M |
4/2018 | Jabrehoo Med Tech | Corporate Round | - |
7/2020 | Harbour Biomed | Series C | 0 |
1/2019 | Hotgen | Series B | 3M |
4/2019 | Sinopharm Online | Series B | 44.6M |
1/2022 | Cloudbreak Therapeutics | Series C | 0 |
9/2017 | LIGOO | Series B | 3.1M |
2/2010 | LIGOO | Series A | 1.4M |
8/2018 | Lachesis | Series B | 29M |
7/2017 | USCI medical laboratory | Series A | 25.1M |
1/2022 | Atom Bioscience &a; Pharmaceutical | Series C | 45M |
5/2011 | Shenzhen Qiche Wang | Angel Round | 462.6k |
11/2017 | Annoroad | Series C | 105.5M |
8/2017 | Akeso Biopharma | Series B | 45.5M |
3/2016 | Vanguarj | Venture Round | 7.7M |
1/2017 | Mabworks | Series B | 39.2M |
4/2019 | Yao123.com | Series B | 0 |
3/2017 | Kangnuo | Angel Round | 434.2k |
4/2018 | Innovative Cellular Therapeutics | Series B | 28.6M |
12/2013 | Anda Exhibition | Angel Round | 493.5k |
8/2010 | Herun Media Group | Series B | 8.8M |
8/2018 | 7LeKang (7lk) | Corporate Round | - |
12/2017 | Henlius | Venture Round | 190M |
2/2021 | Teligene | Series C | 92.9M |
10/2016 | BIOVALLEY | Post-IPO Equity | 22.3M |
12/2013 | Xuele Zhongguo | Angel Round | 1.5M |
1/2013 | Xueleyun | Angel Round | 1.4M |
6/2012 | Supoin | Series C | 4.7M |
3/2022 | TenNor Therapeutics | Series D | 0 |
3/2022 | TenNor Therapeutics | Series D | 0 |
1/2022 | Atom Bioscience &a; Pharmaceutical | Series C | 0 |
1/2022 | Cloudbreak Therapeutics | Series C | 0 |
12/2021 | DK MedTech | Series C | - |
8/2021 | Boan Biotech | Series B | 0 |
4/2021 | VivaVision Biotech | Series D | 0 |
2/2021 | Teligene | Series C | 0 |
7/2020 | Harbour Biomed | Series C | 0 |
1/2020 | Lachesis | Series B | 0 |
1/2020 | CF PharmTech | Series E | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|